Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression

International Journal of Neuropsychopharmacology

Volumn 16, Issue 9, 2013, Pages 2111-2117

  Lara, Diogo R ^a   Bisol, Luisa W ^a   Munari, Luciano R ^b  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b Hospital Espirita de Marília   (Brazil)

Author keywords

Antidepressant; depression; ketamine; mood stabilizer; sleep

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMISULPRIDE; ARIPIPRAZOLE; CITALOPRAM; CLONAZEPAM; DESVENLAFAXINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; KETAMINE; KETOCONAZOLE; LAMOTRIGINE; LITHIUM; METHYLPHENIDATE; MIRTAZAPINE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; OXCARBAZEPINE; PAROXETINE; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SULPIRIDE; TOPIRAMATE; TRAZODONE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE;

ADULT; AGED; AGITATION; ANTIDEPRESSANT ACTIVITY; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CYCLOTHYMIA; DISSOCIATIVE DISORDER; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSTHYMIA; EUPHORIA; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR DEPRESSION; MALE; MENTAL PATIENT; MOOD; OUTPATIENT; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; REMISSION; SIDE EFFECT; SLEEP QUALITY;

ADMINISTRATION, SUBLINGUAL; ADULT; AFFECT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; COGNITION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KETAMINE; MALE; MIDDLE AGED; SLEEP; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883324216     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713000485     Document Type: Article

References (22)

1. Aan Het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ (2010) Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 67:139-145
2. Aan Het Rot M, Zarate CA Jr., Charney DS, Mathew SJ (2012) Ketamine for depression: where do we go from here? Biol Psychiatry 72:537-547
3. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351-354
4. Blonk MI, Koder BG, van den Bemt PM, Huygen FJ (2010) Use of oral ketamine in chronic pain management: a review. Eur J Pain 14:466-472
5. Clements JA, Nimmo WS, Grant IS (1982) Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci 71:539-542
6. Cusin C, Hilton GQ, Nierenberg AA, Fava M (2012) Long-Term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. Am J Psychiatry 169:868-869
7. DiazGranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA Jr. (2010) A randomized add-on trial of an N-methyl-D-Aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67:793-802
8. Duman RS, Aghajanian GK (2012) Synaptic dysfunction in depression: potential therapeutic targets. Science 338:68-72
9. Duncan WC, Sarasso S, Ferrarelli F, Selter J, Riedner BA, Hejazi NS, Yuan P, Brutsche N, Manji HK, Tononi G, Zarate CA (2012) Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol 7:1-11
10. Glue P, Gulati A, Le Nedelec M, Duffull S (2011) Dose- and exposure-response to ketamine in depression. Biol Psychiatry 70:e9-e10
11. Ibrahim L, DiazGranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P, Moaddel R, Wainer I, Luckenbaugh DA, Manji HK, Zarate CA Jr. (2012) Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 37:1526-1533
12. Irwin SA, Iglewicz A (2010) Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. J Palliat Med 13:903-908
13. McNulty JP, Hahn K (2012) Compounded oral ketamine. Int J Pharm Compd 16:364-368
14. Mathew SJ, Murrough JW, Aan Het Rot M, Collins KA, Reich DL, Charney DS (2010) Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 13:71-82
15. Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, Aan Het Rot M, Collins KA, Mathew SJ, Charney DS, Iosifescu DV (2012) Rapid and longer-Term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. Advance online publication. doi:10.1016/j.biopsych.2012.06.022
16. Noppers I, Niesters M, Aarts L, Smith T, Sarton E, Dahan A (2010) Ketamine for the treatment of chronic non-cancer pain. Expert Opin Pharmacother 11:2417-2429
17. Paslakis G, Gilles M, Meyer-Lindenberg A, Deuschle M (2010) Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series. Pharmacopsychiatry 43:33-35
18. Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B, Krystal JH, Sanacora G (2011) The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res 191:122-127
19. Yanagihara Y, Ohtani M, Kariya S, Uchino K, Hiraishi T, Ashizawa N, Aoyama T, Yamamura Y, Yamada Y, Iga T (2003) Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos 24:37-43
20. Zanicotti CG, Perez D, Glue P (2012) Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. J Palliat Med 115:400-403
21. Zarate CA Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-Aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856-864.
22. Zarate CA, Brutsche NE, Ibrahim L, Franco-Chaves J, DiazGranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA (2012) Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 71:939-946.